News Kommuniqué II
Melbourne, Australia, 12 January 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
News Communiqué II
Download the PDF Authorised for ASX release by the Board of Directors...
Read More
News Communiqué I - Maestro Jaap van Zweden
Introducing CLINUVEL Intriguing Personality (CUVIP), Maestro Jaap van Zweden.
Read More
CLINUVEL launches CYACÊLLE, Next Generation Solar Care
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
CYACÊLLE Polychromatic Solar Care – λ3
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Chair's Letter
Melbourne, Australia, 09 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Technical Note: Developing a melanocortin pipeline
CLINUVEL today announced an update on its commercial development of the analogue...
Read More
NEURACTHEL® manufacturing processes advance
CLINUVEL today announced an update on its commercial development of the analogue...
Read More
CLINUVEL Communiqué VI
Melbourne, Australia, 23 December 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Jefferies London Healthcare Conference
CLINUVEL's Chief Executive Officer, Dr Philippe Wolgen, presents to the Jefferies Healthcare...
Read More
CLINUVEL Communiqué V
News Communiqué V discusses CLINUVEL's strong financial results in the face of...
Read More